CAS: 199807-35-7; 2-((2S,5R,8S,11S)-5-Benzyl-11-(3-Guanidinopropyl)-8-Isopropyl-7-Methyl-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-yl)Acetic Acid Trifluoroacetate
- 英文名称2-((2S,5R,8S,11S)-5-Benzyl-11-(3-Guanidinopropyl)-8-Isopropyl-7-Methyl-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-yl)Acetic Acid Trifluoroacetate
- 中文名称西仑吉肽TFA
- IUPAC名称2,2,2-trifluoroacetic acid--2-((2S,5R,8S,11S)-5-benzyl-11-(3-guanidinopropyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid (1/1)
- CAS编号199807-35-7
- MFCD编号:MFCD22665738
- FDA UNII编号:Q8XKR58FVT
- 分子式:C29H41F3N8O9分子量:702.69
- 产品CID: 1015818
- 同类组份化合物CAS199807-35-7 (TFA)188968-51-6 (free base)188969-00-8 (HCl)
- 产品分类生物化工 → 抑制剂
物理性质
- 溶解性DMSO:100.0(Max Conc. mg/mL);142.31(Max Conc. Mm) Water:15.63(Max Conc. mg/mL);22.24(Max Conc. Mm)
- 外观形态白色至类白色固体
- 储存条件惰性气氛,存放于冰箱中, -20°C
- 产品应用该化合物是一种强效异丙酯抑制剂,在无细胞实验中,其抗体分别以4.1 NM和79 NM的异丙基50 值的异丁酯受体对ΑVΒ3 和ΑΒ5 受体进行抗体抑制,其IC50值分别为4.1 NM和79 NM,显示对GPIIBIIIA的选择性程度约为10倍;它是一种环球五溴二苯醚,它模拟了正丙烯-甘油-异丙酸(RGD)序列,具有竞争性地抑制了异丙醇-异丁酸的结合;它有选择地和有效地阻断了ΑΒ3和Α-Β5与异丁基细胞外细胞蛋白质的相互作用,例如,例如异丙酮素,异丙苯丙胺,纤维素,纤维激素,VON WILLEBRAND因因因和骨质锡;它抑制异丙胺细胞的抗体激性,扩散和诱导体在异体内和肿瘤细胞内诱发性诱发;它压制了人类内泌细胞细胞细胞的分泌;
合成工艺路线路线简述
📜,三氟乙酸 以 水 用作溶剂,化学反应生成西仑吉肽tfa
参考文献:Methods For Treatment Of Tumors And Metastases Using A Combination Of Anti-Angiogenic And Immuno Therapies
标题:Methods For Treatment Of Tumors And Metastases Using A Combination Of Anti-Angiogenic And Immuno Therapies
摘要:该发明教授了治疗哺乳动物肿瘤和肿瘤转移的方法,包括向需要治疗的哺乳动物注射治疗剂量的拮抗剂,足以抑制血管生成,并与治疗剂量的抗肿瘤免疫治疗剂联合使用,例如抗肿瘤抗原抗体/细胞因子融合蛋白,具有细胞因子和重组免疫球蛋白多肽链,足以引起细胞因子特异性生物反应.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Kang HE, Seo Y, Kim Y, Kim J. Combined treatment of TKIs with Cilengitide overcomes afatinib-resistance in EGFR-mutated NSCLC cells. Mol Biol Rep. 2025 Dec 29;53(1):233. doi: 10.1007/s11033-025-11405-2. 54(7):597-606. doi: 10.1111/jop.70004. Epub 2025 Jul 1. 26(1):187. doi: 10.1186/s13058-024-01942-2.
4: Guo DY, Chen ZH, Fu YF, Li YY, Chen MN, Wu JJ, Yuan ZD, Ye JX, Li X, Yuan FL. Corrigendum to "Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway" [Heliyon 9(7) (July 2023) e17841]. Heliyon. 2023 Nov 24;10(1):e22629. doi: 10.1016/j.heliyon.2023.e22629. Erratum for: Heliyon. 2023 Jun 29;9(7):e17841. doi: 10.1016/j.heliyon.2023.e17841.
5: Flies CM, Friedrich M, Lohmann P, van Garderen KA, Smits M, Tonn JC, Weller M, Galldiks N, Snijders TJ. Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide. Neuro Oncol. 2024 May 3;26(5):902-910. doi: 10.1093/neuonc/noad247.
📝 需求与反馈
尽可能描述清楚需求与问题信息
